FDA hearings this week on “pink viagra”

The Food and Drug Administration will be deliberating the possible approval of a new drug meant to increase women’s sex drive, Flibanserin, on Thursday of this week.
Jessica Vanessa already talked about how it’s the least appealing name for a sex drug ever created, and the New View Campaign thinks medicalizing women’s sexuality for pharmaceutical profit is a terrible idea.
I do think it’s interesting that this drug was originally an anti-depressant, as Jessica Vanessa pointed out. They do say the brain is our biggest and most important sex organ, but it’s hard to trust the pharmaceutical industry with a concern for women’s sexual health and well-being. The application calls Flibanserin a “treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.”
Who decides what is hypoactive (aka not active enough or under active) sexual desire anyway?
In my opinion, sexual desire is not something that can be measured independently, most frequently what becomes an issue is how it compares to that of your partner (if there is a partner involved). Women are stereotyped with never wanting sex and men with always wanting it, but we all know it’s never that simple.